BioCentury
ARTICLE | Clinical News

Allovectin-7: Phase II

June 9, 2003 7:00 AM UTC

Interim data from a U.S. Phase II trial showed 12 of 91 (13%) patients given high dose (2 mg) Allovectin-7 had objective responses. VICL said this compares to a 10-12% response rate for dacarbazine in...